Comparative Pharmacology
Head-to-head clinical analysis: DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5 IN PLASTIC CONTAINER versus DOBUTREX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5 IN PLASTIC CONTAINER versus DOBUTREX.
DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER vs DOBUTREX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dobutamine is a direct-acting inotropic agent whose primary activity results from stimulation of the beta-1 adrenergic receptors of the heart, increasing contractility and cardiac output. It also has mild beta-2 and alpha-1 receptor activity.
Dobutamine is a direct-acting inotropic agent primarily stimulating beta-1 adrenergic receptors, with mild beta-2 and alpha-1 effects. It increases myocardial contractility and stroke volume, resulting in increased cardiac output.
Continuous IV infusion: 2.5 to 20 mcg/kg/min; titrate to desired hemodynamic response. Maximum dose: 40 mcg/kg/min.
2.5-20 mcg/kg/min continuous IV infusion; titrate to hemodynamic response.
None Documented
None Documented
Terminal elimination half-life is approximately 2 minutes for the parent drug (dobutamine) due to rapid metabolism by COMT. In clinical context, the effect half-life is about 2–3 minutes, requiring continuous intravenous infusion to maintain steady-state concentrations.
Terminal elimination half-life approximately 2 minutes; clinical effects wane within minutes of infusion cessation due to rapid redistribution and metabolism
Primarily renal excretion of metabolites (catechol-O-methyltransferase conjugates) and unchanged drug: approximately 80% renal, 20% biliary/fecal. Less than 5% excreted unchanged in urine.
Renal: 75-80% as metabolites (3-O-methyl-dobutamine and conjugates) and unchanged drug; minor biliary/fecal elimination (<5%)
Category C
Category C
Inotropic Agent
Inotropic Agent